By RTT News, April 19, 2013, 09:27:00 AM EDT
(RTTNews.com) - Healthcare company BioTime, Inc. ( BTX ) Friday said it has entered into an exclusive license agreement with the University of California, Los Angeles, or UCLA, for the development of technology related to the treatment of stroke.
The company said the licensed technology, developed in the labs of Tom Carmichael, MD, PhD of UCLA'sDepartment of Neurology, at the David Geffen School of Medicine, uses one of BioTime's HyStem hydrogels to deliver locally released growth factors to improve recovery from stroke. It further added that pre-clinical studies have demonstrated that the localized delivery of growth factors such as brain-derived neurotrophic factor results in a statistically significant improvement in post-stroke motor function in a murine model of ischemic stroke.
The firm has, at the same time, entered into a Sponsored Research Agreement with UCLA to support the on-going pre-clinical work in Dr. Carmichael's laboratory to advance the understanding of this technology and develop data in support for the potential filing of an Investigational New Drug Application for human clinical trails.
For comments and feedback: contact editorial@rttnews.com
Read the original post:
BioTime Enters Into License Agreement With UCLA To Develop Therapy For Stroke